Novo Nordisk (NVO) has released an update. Don't Miss our Black Friday Offers: Novo Nordisk has launched a share repurchase program, aiming to buy back B shares worth up to DKK 20 billion over a ...

Over the last couple of years, Danish company Novo Nordisk (NYSE: NVO) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's ...

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk continues to witness strong growth across its portfolio of diabetes and obesity care medications. The company's tailwinds include expanded indications and new geographic markets.

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.

As Sen. Bernie Sanders (I-Vt.) noted in a September Senate hearing, Wegovy, made by Novo Nordisk, is sold for $265 in Canada, $186 in Denmark, $137 in Germany, and just $92 in the United Kingdom.

Novo Nordisk NOVO.B-1.53%decrease; red down pointing triangle has launched its blockbuster Wegovy weight-loss drug in China, adding the world’s second-largest economy to its growing list of ...

UBS analyst Jo Walton maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,100.00. The company’s shares closed last Friday at DKK721.01.

Novo Nordisk, the maker of weight-loss drugs Ozempic and Wegovy, is suing at least five Chicago-area medical spas and health clinics, alleging they each are using false advertising and deceptive ...